Reactions 1680, p199 - 2 Dec 2017
Pulmonary embolism, deep vein thrombosis and
cardiac arrest: case report
In a retrospective study of clinical trial NCT02341781
(MCL-004 study), a 68-year-old man was described, who
developed pulmonary embolism, deep vein thrombosis (DVT)
and cardiac arrest during treatment with lenalidomide [IMid].
Subsequently, he died.
The man, who had a history of mantle cell lymphoma, was
started on oral lenalilomide [dosage not stated]. Two months
after the start of the treatment, he had a partial response.
However, 83 days after the first dose of lenalidomide, he died
because of pulmonary embolism, which was suspected to be
related to the lenalidomide. Additionally, he experienced grade
five adverse events deep vein thrombosis and cardiac arrest.
Author comment: "This patient had a (partial response) 2
months after lenalidomide initiation but died due to a
pulmonary embolism, suspected to be related to
lenalidomide therapy, as well as had incidences of other
grade 5 AEs (DVT and cardiac arrest). "
Wang M, et al. Observational study of lenalidomide in patients with mantle cell
lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib
(MCL-004). Journal of Hematology and Oncology 10: 171, 2 Nov 2017. Available
from: URL: http://doi.org/10.1186/s13045-017-0537-5 - USA
Reactions 2 Dec 2017 No. 16800114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved